News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–72
Matches
49161
Sources here
17
Companies here
43
Search results Stored financial headlines

Active search

49161 matching headlines

Ticker or company: ITEMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Alibaba to Sell Gaming Arm for $1.5 Billion in Boost to AI Pivot

(Bloomberg) -- Alibaba Group Holding Ltd. is selling its gaming arm in a deal worth at least $1.5 billion that will boost the Chinese e-commerce leader's pivot to AI. Most Read from Bloomberg Covert Mideast Oil Flows Are Keeping Global Prices in Check Anthropic …

BABA main company BABA80 main company BABA01 main company BABAN main company 9988 main company BABA34 main company +5 more
Sharemaestro market context Price below Trend Line 52 weeks +18.9% · Next-week setup positive 56.3% BABA stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Tencent Details Progress Toward Carbon Neutrality Goals and Outlines AI-Era Priorities

New report outlines how infrastructure efficiency, renewable electricity and AI-enabled innovation can support lower-carbon growth SHENZHEN, China, Aug. 16, 2026 /PRNewswire/ -- Tencent (0700.HK) published its Carbon Neutrality Mid-Term Report and launched an accompanying interactive microsite, sharing its progress to date and pathway toward …

TCEHYN main company 0700 main company NNND main company NNN1 main company TENCENT11 main company HTCD main company
Sharemaestro market context Price below Trend Line 52 weeks -32.1% TCEHYN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Limited NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic …

MSB main company
Sharemaestro market context Price above Trend Line 52 weeks -7.1% MSB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®

HUTCHMED (China) Limited — First global Phase III trial to show significant progression-free and overall survival benefits in this setting — — SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm lung cancer — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., …

0013 main company HCM main company
Sharemaestro market context New activity signal 52 weeks -24.4% 0013 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Archer Guided to a $200 Million Quarterly Loss. It Has About $1.6 Billion.

Archer Aviation (NYSE: ACHR) reported its second-quarter results on Monday, and the two numbers that matter most sit at opposite ends of the release. The air taxi maker expects an adjusted EBITDA loss of $170 million to $200 million for the third quarter. And …

ARCH main company
Sharemaestro market context Price below Trend Line 52 weeks +12.3% ARCH stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Golar LNG (GLNG) Stock Looks Below Fair Value After a Huge Run

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Golar LNG has delivered a very large 5 year return while the broader valuation checks now point to a more mixed picture rather than a …

GLNG main company
Sharemaestro market context Trend signal active 52 weeks +19.7% GLNG stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context